Optimizing the treatment of liver metastases from uveal melanomas with transarterial chemoembolization using melphalan and calibrated microspheres - 09/12/20
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Introduction |
Patients with liver metastasis from uveal melanoma have a poor prognosis. Efficacy and safety of hepatic transarterial chemoembolization (TACE) using melphalan and microspheres was evaluated.
Materials and methods |
Monocentric retrospective study of all consecutive patients treated by TACE using melphalan and 250μm calibrated microspheres between 2004 and 2016. Radiological response was assessed according to RECIST 1.1, modified (m)-RECIST and EASL on contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI). The primary endpoint was overall survival (OS). Liver metastasis response, hepatic, extrahepatic and global progression free survival (PFS) complications were evaluated with the common terminology criteria for adverse events version 4.0 (CTCAE 4.0) and survival factors were secondary endpoints.
Results |
Thirty-four patients underwent 138 TACE (4; 4.1 sessions; range 1–9). Median OS was 16.5 months (mean 21.6 months). Liver metastasis response combining partial and complete response was 42.4%, 97%, 97% with RECIST 1.1, mRECIST, EASL, respectively. There were 58 severe (CTCAE≥3) but manageable complications in 28 patients, except for 1 toxic death.
Conclusion |
For patients with liver metastases from uveal melanoma ineligible for local treatments, TACE using melphalan may be performed as first line therapy in metastatic miliary disease from uveal melanomas with careful supportive care.
Le texte complet de cet article est disponible en PDF.Keywords : Melanoma, Metastasis, Liver, Embolization, Chemotherapy
Plan
Vol 107 - N° 12
P. 1274-1283 - décembre 2020 Retour au numéro
Article précédent
- Quoi de neuf dans la prise en charge des tumeurs fibreuses solitaires/hémangiopéricytomes des méninges ?
- Marine Lottin, Alexandre Escande, Matthieu Peyre, Henri Sevestre, Claude Alain Maurage, Bruno Chauffert, Nicolas Penel
- 3e colloque de recherche fondamentale en oncologie pédiatrique
- Véronique Trézéguet, Sarah Lesjean, Philippe Veschambre, Patrick Auguste, Béatrice Turcq, Stéphane Ducassou, Aksam Merched, Christophe F. Grosset
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?